These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338 [TBL] [Abstract][Full Text] [Related]
10. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Panaccione R; Danese S; Sandborn WJ; O'Brien CD; Zhou Y; Zhang H; Adedokun OJ; Tikhonov I; Targan S; Abreu MT; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Arasaradnam RP; Sands BE; Marano C Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1658-1675. PubMed ID: 33086438 [TBL] [Abstract][Full Text] [Related]
12. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C; N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833 [TBL] [Abstract][Full Text] [Related]
13. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329 [TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States. Hong SJ; Krugliak Cleveland N; Akiyama S; Zullow S; Yi Y; Shaffer SR; Malter LB; Axelrad JE; Chang S; Hudesman DP; Rubin DT Crohns Colitis 360; 2021 Jan; 3(1):otab002. PubMed ID: 36777067 [TBL] [Abstract][Full Text] [Related]
15. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444 [TBL] [Abstract][Full Text] [Related]
16. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446 [TBL] [Abstract][Full Text] [Related]
17. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718 [TBL] [Abstract][Full Text] [Related]
18. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763 [TBL] [Abstract][Full Text] [Related]
20. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ; Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]